<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The synergistic effect of <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA), a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor, were investigated in this study </plain></SENT>
<SENT sid="1" pm="."><plain>Co-treatment with VPA and <z:chebi fb="0" ids="52717">bortezomib</z:chebi> on <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) cell lines resulted in marked inhibition of proliferation and induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, including a striking increase in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> injury, caspase cascade activation, and altered expression of Bcl-2 family proteins </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, combination treatment inhibited cyto-protective signaling pathways, including inactivation of nuclear factor κB (NF-κB), the extracellular signal-related kinase (ERK) and Akt pathways, and activated stress-related signaling pathway, including the c-jun N-terminal kinase (JNK) and p38 <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (p38) pathways </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, this regimen significantly caused G2/M phase arrest, while downregulating the expression of phospho-CDC2 and CyclinD1 as well as increasing p21(cip1) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, combination treatment efficiently induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in primary <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> cells, with little effect on <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="5" pm="."><plain>In summary, these findings indicate that combination treatment with VPA and <z:chebi fb="0" ids="52717">bortezomib</z:chebi> may be a potent therapy for <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>